Clinical Trial

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Name: IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer — clinical trial record (NCT07722494)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-11

Trial Details

NCT Number	NCT07722494
Lead Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Colorectal Cancer
Enrollment	550 participants
Start Date	2026-07-31
Primary Completion	2028-10-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10